Is Australia ready for the rollout of amyloid‐targeting therapies for Alzheimer disease? Results from a national survey characterising current infrastructure capability, workforce and training needs of memory and cognition clinics
Australia's health system preparedness for amyloid-targeting mAb therapies will require further investment in infrastructure, equity of access, clinician training and support. Long wait times already impact access to clinics, and with the forecast rise in MCI and dementia cases, services will need to be expanded, and appropriate Models of Care and clear and efficient inter-sector health pathways will be needed to prepare for the use of mAbs.
Authors
- Johannes C. Michaelian (ORCID: https://orcid.org/0000-0001-5683-8222)
- Susan Kurrle (ORCID: https://orcid.org/0000-0003-3448-4181)
- Dimity Pond (ORCID: https://orcid.org/0000-0001-6520-4213)
- Sharon L. Naismith (ORCID: https://orcid.org/0000-0001-9076-2778)
- Michael Woodward (ORCID: https://orcid.org/0000-0002-0414-6977)
- Christopher C. Rowe
Institutions
- The University of Sydney (AU)
- University of Tasmania (AU)
- The University of Melbourne (AU)
- Austin Health (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1111/imj.16637
- Citations
- 3
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 9.39
Funders
- Eli Lilly and Company
- Biogen
- Prothena
- Cerveau Technologies
- University of Sydney
- Eisai
- Australian and New Zealand Society for Geriatric Medicine